Originally published by our sister publication Infectious Disease Special Edition
The FDA expanded the indication for glecaprevir-pibrentasvir (GLE/PIB; Mavyret, AbbVie) to treat adults and pediatric patients 36 months of age and older with acute or chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis.
With this approval, GLE/PIB is the first and only direct-acting antiviral therapy approved to treat patients with acute HCV in eight weeks with a 96% cure